Neuphoria Therapeutics (NEUP) Receivables (2020 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Receivables of $2.4 million for Q1 2026, up 8675.58% year-over-year from $27500.0 in Q1 2025, and up 50.99% quarter-over-quarter from $1.6 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Receivables (2020 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Receivables for 7 consecutive years, with $2.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables rose 8675.58% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (up 8675.58% YoY), while the FY2025 annual figure was $11948.0, down 94.64% from the prior year.
- Receivables rose to $2.4 million in Q1 2026 per NEUP's latest filing, from $1.6 million in the prior quarter.
- Across five years, Receivables topped out at $4.9 million in Q2 2022 and bottomed at $3516.0 in Q3 2025.
- Historically, Receivables has averaged $982085.0 across 5 years, with a median of $219811.5 in 2024.
- Annual changes were most pronounced in 2025 — Receivables slumped 98.38% — and 2026, when it soared 8675.58%.
- Neuphoria Therapeutics' Receivables stood at $4.9 million in 2022, then tumbled by 91.15% to $429864.7 in 2023, then slumped by 91.26% to $37582.0 in 2024, then soared by 4152.78% to $1.6 million in 2025, then surged by 50.99% to $2.4 million in 2026.
- Business Quant data shows NEUP's Receivables at $2.4 million in Q1 2026, $1.6 million in Q4 2025, and $3516.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.75 Bn | 130.90 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.96 Bn | 77.96 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 56.33 Bn | 51.19 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.56 Bn | 28.25 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | - |
| 10 | Neuphoria Therapeutics | 21.37 Mn | 1.93 Mn | - | 2.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.41 Mn |
| Dec 31, 2025 | 1.60 Mn |
| Sep 30, 2025 | 3,516.00 |
| Jun 30, 2025 | 11,948.00 |
| Mar 31, 2025 | 27,500.00 |
| Dec 31, 2024 | 37,582.00 |
| Sep 30, 2024 | 216,585.00 |
| Jun 30, 2024 | 223,038.00 |
| Jun 30, 2023 | 429,864.71 |
| Jun 30, 2022 | 4.86 Mn |
| Jun 30, 2021 | 868,841.66 |
| Jun 30, 2020 | 1.19 Mn |